Skip to main content

Table 2 Treatment strategies for patients with Streptococcal or MSSA PJIs

From: Streptococcal and Staphylococcus aureus prosthetic joint infections: are they really different?

Treatment strategy Streptococcal PJIs
(n = 86)
MSSA PJIs
(n = 123)
P
Exchange arthroplasty 51 (59)a 79 (64) 0.389
Time (days) to prosthesis exchange 22 [5–196] 92 [12–257] 0.062
One-stage exchange 50 (98) 74 (94) 0.670
Two-stage exchange 1 (2) 5 (6) 0.404
DAIR 14 (16) 29 (24) 0.306
Time to DAIR (days) 5 [2–9] 8 [4–12] 0.042
Mobile device exchange 8 (57) 14 (48) 0.51
Definitive prosthesis removal 0 5 0.079
Antibiotics combined with surgery    
Treatment duration (days) 87 [85–92] 87 [64–92] 0.444
IV duration (days) 32 [29–36] 33 [29–44] 0.265
Beta-lactams > 14 days 65 (76) 85 (69)  < 0.0001
Rifampicin > 14 days 29 (35) 88 (73)  < 0.0001
Prolonged suppressive antibiotic therapy 21 (24) 10 (8) 0.001
Initial IV antibiotics 16 (55) 8 (80) 1.000
IV duration (days) 9 [4-23] 16 [11–27] 0.071
Duration (days) 405 [375–741] 366 [136–640] 0.016
  1. DAIR debridement, antibiotics and implant retention, IV intravenous, MSSA methicillin-susceptible Staphylococcus aureus, PJI prosthetic joint infection
  2. aResults are expressed as number (%) or median [interquartile range] for continuous variables